Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leaner Kabi Drives Higher Savings Goal For Fresenius, China ‘Soft’ In 2024

German Firm Commits To 2024 Biosimilars EBITDA Goal In Busy Q4 Call

Executive Summary

Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.

You may also be interested in...



What’s Next? Five Things To Look Out For In March

Generics Bulletin previews the most noteworthy and anticipated events for March 2024.

Kabi Commands Respect As It Launches First Tocilizumab Biosimilar In Europe

Fresenius Kabi has kicked off November by launching its tocilizumab biosimilar Tyenne – the first biosimilar to Actemra to reach the EU.

Fresenius Kabi Reveals €800m Biopharma Ambitions By 2026

During a lengthy and comprehensive capital markets day, Fresenius Kabi spelled out its vision and plans for a return from the company’s burgeoning Biopharmaceuticals business, following years of major investment.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel